Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ammonium lactate
- Development stage
- Approved
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Ammonium lactate is a synthetic alpha-hydroxy acid (AHA) formulated as a topical humectant and keratolytic agent. It is primarily used to treat dry, scaly skin conditions such as xerosis and ichthyosis vulgaris, and has been investigated as a monotherapy or maintenance treatment for chronic plaque psoriasis. The drug works by increasing skin hydration through its humectant properties and promoting the shedding of dead skin cells (desquamation) by reducing corneocyte adhesion in the stratum corneum. It is commonly available in 12% concentrations as a lotion or cream.
- Brand names
- AmLactinLac-HydrinGeri-Hydrolac
- Other names
- Lactic acid ammonium saltAmmonium 2-hydroxypropanoateAmmonium2-hydroxypropanoateAmmonium-2-hydroxypropanoate
Beyond the preview
Go deeper on ammonium lactate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ammonium lactate.